Category: MS Drug Therapies

TG Therapeutics Announces FDA Acceptance of Biologics License Application for Ublituximab as a Treatment for Patients with Relapsing Forms of Multiple Sclerosis

 December 14, 2021 (Globe Newswire) Prescription Drug User Fee Act (PDUFA) goal date of September 28, 2022 TG Therapeutics, Inc.…

Stuart Schlossman

mRNA COVID-19 vaccines effective in patients with MS on disease-modifying therapies

December 3, 2021 Messenger RNA COVID-19 vaccination was effective among most patients with MS who used various disease-modifying therapies, according…

Stuart Schlossman

Relapse comparable among common DMTs for MS

Dimethyl fumarate and fingolimod appeared to have no significant difference in relapse rates, and rituximab appeared to have better relapse…

Stuart Schlossman

Timing of rituximab infusion not tied to risk for COVID-19 hospitalization

 December 6, 2021 The timing of rituximab infusion or cumulative lifetime rituximab dose did not appear statistically significantly associated with…

Stuart Schlossman

Siponimod’s Efficacy on Secondary Progressive MS in Older age groups

 October 28, 2021   –    Le Hua, MD ranscript below. Le Hua, MD: The original EXPAND study had been presented, so…

Stuart Schlossman

Evaluate the efficacy and safety of alemtuzumab in CARE-MS II patients over 10 years

Knowing what MS can do to people and seeing these results who wouldn’t want to be treated with, or at…

Stuart Schlossman

BTK Inhibitor Reduces New Lesions in Relapsing Multiple Sclerosis

 Tolebrutinib may hold promise for progressive MS, too by Judy George, Senior Staff Writer, MedPage Today September 3, 2021    Tolebrutinib, a…

Stuart Schlossman

BTK Inhibitor Fenebrutinib Aims to Tackle Progressive MS in FENtrepid Trial

 August 20, 2021        – Marco Meglio NeurologyLive, August 2021, Volume 4, Issue 4 The agent’s safety profile has been studied in…

Stuart Schlossman

6-Week Dosing of Natalizumab Effective, May Reduce PML Risk

August 3, 2021 –   Abby Reinhard  Efficacy data from a trial examining extended dosing adds to real-world data that demonstrates…

Stuart Schlossman

Trial Will Test Mavenclad for Advanced Progressive MS

 After some delays due to the COVID-19 pandemic, the Phase 2/3 clinical trial evaluating whether Mavenclad (cladribine) can slow hand and arm…

Stuart Schlossman

Categories

Latest Blog Posts